Clinical trial · Interventional
Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies
Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies: a Clinical Phase I Trial
NCT02702700CI-TRIAL-00037715PDT-lipoterminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Drug supply issue
Summary
Brief summary (as posted)
This clinical study aims to explore intrapleural low-dose Visudyne®-mediated photodynamic therapy (photo-induction) as a pathway to promote the uptake of systemically administered Lipoplatin™ in pleural malignancies of patients undergoing video-assisted talcage for their malignant pleural effusions. Photo-induction is expected to overcome the chemo-resistance of pleural malignancies for cisplatin-based chemotherapeutics and thereby improve local tumor control.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pleural Effusion, Malignant | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin, liposomal | Drug | — | UNRESOLVED |
| Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry | Device | — | UNRESOLVED |
| Verteporfin | Drug | Verteporfin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Lipoplatin/Visudyne-mediated photodynamic therapy
- description
- 200 mg/m2 Lipoplatin™ will be delivered as iv perfusion. Then, intrapleural photo-induction will be realized through a classical video-assisted thoracoscopic (VATS) approach using 3 mg/m2 Visudyne® activated at 689 nm. At the end of the procedure, the patients will receive chemical pleurodesis by VATS as per standard-of-care treatment for malignant pleural effusion.
- interventionNames
- Drug: Cisplatin, liposomal
- Drug: Verteporfin
- Device: Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry
Primary outcomes (7)
- measure
- Safety of the treatment as assessed by 30-day postoperative mortality
- timeFrame
- 30 days
- description
- survival status at 30 days
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion criteria * Stage IV breast, ovarian, gastric, colorectal, germ cell, lung, bladder, sarcoma or head and neck carcinoma requiring systemic chemotherapy OR alternatively * Stage I/II malignant pleural mesothelioma OR alternatively * Stage III/IV mesothelioma requiring systemic chemotherapy OR alternatively * Stage IVa thymic malignancies AND * Cytologically proven malignant pleural effusion requiring VATS pleurodesis * PS 0-1 * Age 18-80 * Written informed content * Life expectancy \>3 months * Laboratory Requirements - within 28 days prior to enrollment: * Haematology: * absolute granulocytes ≥1× 109/L * platelets ≥100 × 109/L * leukocytes ≥3 × 109 * Biochemistry: * Bilirubin ≤3 × upper limit of normal (\<5x if liver metastasis present) * AST(SGOT) ≤2.5 × upper limit of normal (\<5x if liver metastasis present) * Creatinine clearance ≥50 mL/min according to Cockroft and Gault * No major cardio-pulmonary co-morbidity precluding a surgical approach according to local standards * Enrollment decision at the institutional multidisciplinary tumor board * Patient must be willing to use effective methods of contraception. Female patients must be postmenopausal, surgically sterile, or they must agree to use a physical barrier method of contraception in addition to either an intrauterine device or hormonal contraception until at least of 3 months after the study treatment. Male patients must agree to use a barrier method (condom) for 3 months after study treatment. Exclusion criteria * Grade \>2 peripheral neuropathy * Any concurrent anticancer systemic therapy within 14 days before the study intervention * Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study e.g. Known or suspected allergy to the investigational agent or any agent given in association with this trial. Clinically serious infections requiring systemic antibiotic (e.g antiviral, antimicrobial, antifungal) therapy. * Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results * Severe interstitial pneumonia or pulmonary fibrosis * Chronic corticosteroid use at equivalent dose of \>30mg/d methylprednisolone * Pregnancy or breast-feeding * Porphyria * Severe liver insufficiency
References
Publications (0)
Data not yet available
No reference posted for this study.